Anúncio
Anúncio

STRO

STRO logo

Sutro Biopharma, Inc.

11.47
USD
Patrocinado
+0.61
+5.57%
06 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

11.41

-0.06
-0.52%

Relatórios de Lucros STRO

Rácio de surpresa positiva

STRO separação 14 de 29 últimas estimativas.

48%

Próximo Relatório

Data do Próximo Relatório
11 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.51M
/
-$4.40
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-12.23%
/
-34.33%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-42.55%
/
-50.56%

Sutro Biopharma, Inc. earnings per share and revenue

On 06 de nov. de 2025, STRO reported earnings of -6.70 USD per share (EPS) for Q3 25, missing the estimate of -4.22 USD, resulting in a -58.49% surprise. Revenue reached 9.69 milhão, compared to an expected 9.31 milhão, with a 4.07% difference. The market reacted with a -13.36% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analistas forecast an EPS of -4.40 USD, with revenue projected to reach 8.51 milhão USD, implying an diminuir of -34.33% EPS, and diminuir of -12.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
For Q3 2025, Sutro Biopharma, Inc. reported EPS of -$6.70, missing estimates by -58.49%, and revenue of $9.69M, 4.07% above expectations.
The stock price moved down -13.36%, changed from $9.42 before the earnings release to $8.16 the day after.
The next earning report is scheduled for 11 de mar. de 2026.
Based on 12 analistas, Sutro Biopharma, Inc. is expected to report EPS of -$4.40 and revenue of $8.51M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio